1
|
Mankin EA, Aghajan ZM, Schuette P, Tran ME, Tchemodanov N, Titiz A, Kalender G, Eliashiv D, Stern J, Weiss SA, Kirsch D, Knowlton B, Fried I, Suthana N. Stimulation of the right entorhinal white matter enhances visual memory encoding in humans. Brain Stimul 2021; 14:131-140. [PMID: 33279717 PMCID: PMC7855810 DOI: 10.1016/j.brs.2020.11.015] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 09/15/2020] [Accepted: 11/16/2020] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND While deep brain stimulation has been successful in treating movement disorders, such as in Parkinson's disease, its potential application in alleviating memory disorders is inconclusive. OBJECTIVE/HYPOTHESIS We investigated the role of the location of the stimulating electrode on memory improvement and hypothesized that entorhinal white versus gray matter stimulation would have differential effects on memory. METHODS Intracranial electrical stimulation was applied to the entorhinal area of twenty-two participants with already implanted electrodes as they completed visual memory tasks. RESULTS We found that stimulation of right entorhinal white matter during learning had a beneficial effect on subsequent memory, while stimulation of adjacent gray matter or left-sided stimulation was ineffective. This finding was consistent across three different visually guided memory tasks. CONCLUSIONS Our results highlight the importance of precise stimulation site on modulation of human hippocampal-dependent memory and suggest that stimulation of afferent input into the right hippocampus may be an especially promising target for enhancement of visual memory.
Collapse
Affiliation(s)
- Emily A Mankin
- Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA
| | - Zahra M Aghajan
- Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, University of California, Los Angeles, 760 Westwood Plaza, Los Angeles, CA, 90095, USA
| | - Peter Schuette
- Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, University of California, Los Angeles, 760 Westwood Plaza, Los Angeles, CA, 90095, USA; Department of Bioengineering, University of California, Los Angeles, 410 Westwood Plaza, Los Angeles, CA, 90095, USA
| | - Michelle E Tran
- Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA
| | - Natalia Tchemodanov
- Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA
| | - Ali Titiz
- Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA
| | - Güldamla Kalender
- Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA
| | - Dawn Eliashiv
- Department of Neurology, University of California, Los Angeles, 710 Westwood Plaza, Los Angeles, CA, 90095, USA
| | - John Stern
- Department of Neurology, University of California, Los Angeles, 710 Westwood Plaza, Los Angeles, CA, 90095, USA
| | - Shennan A Weiss
- Department of Neurology, University of California, Los Angeles, 710 Westwood Plaza, Los Angeles, CA, 90095, USA
| | - Dylan Kirsch
- Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, University of California, Los Angeles, 760 Westwood Plaza, Los Angeles, CA, 90095, USA
| | - Barbara Knowlton
- Department of Psychology, University of California, Los Angeles, 502 Portola Plaza, Los Angeles, CA, 90095, USA
| | - Itzhak Fried
- Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA; Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, University of California, Los Angeles, 760 Westwood Plaza, Los Angeles, CA, 90095, USA; Functional Neurosurgery Unit, Tel-Aviv Medical Center and Sackler School of Medicine, Tel-Aviv University, P.O.B 39040 Ramat Aviv, Tel-Aviv, 69978, Israel
| | - Nanthia Suthana
- Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA; Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, University of California, Los Angeles, 760 Westwood Plaza, Los Angeles, CA, 90095, USA; Department of Psychology, University of California, Los Angeles, 502 Portola Plaza, Los Angeles, CA, 90095, USA; Department of Bioengineering, University of California, Los Angeles, 410 Westwood Plaza, Los Angeles, CA, 90095, USA.
| |
Collapse
|
2
|
Abstract
Presynaptic receptors are sites at which transmitters, locally formed mediators or hormones inhibit or facilitate the release of a given transmitter from its axon terminals. The interest in the identification of presynaptic receptors has faded in recent years and it may therefore be justified to give an overview of their occurrence in the autonomic and central nervous system; this review will focus on presynaptic receptors in human tissues. Autoreceptors are presynaptic receptors at which a given transmitter restrains its further release, though in some instances may also increase its release. Inhibitory autoreceptors represent a typical example of a negative feedback; they are tonically activated by the respective endogenous transmitter and/or are constitutively active. Autoreceptors also play a role under pathophysiological conditions, e.g. by limiting the massive noradrenaline release occurring during congestive heart failure. They can be used for therapeutic purposes; e.g., the α2-adrenoceptor antagonist mirtazapine is used as an antidepressant and the inverse histamine H3 receptor agonist pitolisant has been marketed as a new drug for the treatment of narcolepsy in 2016. Heteroreceptors are presynaptic receptors at which transmitters from adjacent neurons, locally formed mediators (e.g. endocannabinoids) or hormones (e.g. adrenaline) can inhibit or facilitate transmitter release; they may be subject to an endogenous tone. The constipating effect of the sympathetic nervous system or of the antihypertensive drug clonidine is related to the activation of inhibitory α2-adrenoceptors on postganglionic parasympathetic neurons. Part of the stimulating effect of adrenaline on the sympathetic nervous system during stress is related to its facilitatory effect on noradrenaline release via β2-adrenoceptors.
Collapse
Affiliation(s)
| | - Thomas Feuerstein
- Sektion Neuroelektronische Systeme, Klinik für Neurochirurgie, Universität Freiburg, Germany
| |
Collapse
|
3
|
Niewiadomska G, Baksalerska-Pazera M, Riedel G. The septo-hippocampal system, learning and recovery of function. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:791-805. [PMID: 19389457 DOI: 10.1016/j.pnpbp.2009.03.039] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2009] [Accepted: 03/30/2009] [Indexed: 12/23/2022]
Abstract
We understand this review as an attempt to summarize recent advances in the understanding of cholinergic function in cognition. Such a role has been highlighted in the 1970s by the discovery that dementia patients have greatly reduced cholinergic activity in cortex and hippocampus. A brief anatomical description of the major cholinergic pathways focuses on the basal forebrain and its projections to cortex and hippocampus. From this distinction, compelling evidence suggests that the basal forebrain --> cortex projection regulates the excitability of principal cortical neurons and is thereby critically involved in attention, stimulus detection and memory function, although the biological conditions for these functions are still debated. Similar uncertainties remain for the septo-hippocampal cholinergic system. Although initial lesions of the septum caused memory deficits reminiscent of hippocampal ablations, recent and more refined neurotoxic lesion studies which spared non-cholinergic cells of the basal forebrain failed to confirm these memory impairments in experimental animals despite a near total loss of cholinergic labeling. Yet, a decline in cholinergic markers in aging and dementia still stands as the most central piece of evidence for a link between the cholinergic system and cognition and appear to provide valuable targets for therapeutic approaches.
Collapse
|
4
|
Jackisch R, Gansser S, Cassel JC. Noradrenergic denervation facilitates the release of acetylcholine and serotonin in the hippocampus: Towards a mechanism underlying upregulations described in MCI patients? Exp Neurol 2008; 213:345-53. [DOI: 10.1016/j.expneurol.2008.06.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2008] [Revised: 06/12/2008] [Accepted: 06/14/2008] [Indexed: 12/25/2022]
|
5
|
Abstract
Presynaptic receptors for dopamine, histamine and serotonin that are located on dopaminergic, histaminergic and sertonergic axon terminals, respectively, function as autoreceptors. Presynaptic receptors also occur as heteroreceptors on other axon terminals. Auto- and heteroreceptors mainly affect Ca(2+) -dependent exocytosis from the receptor-bearing nerve ending. Some additionally subserve other presynaptic functions.Presynaptic dopamine, histamine and serotonin receptors are involved in various (patho)physiological conditions. Examples are the following:Dopamine autoreceptors play a role in Parkinson's disease, schizophrenia and drug addiction. Dopamine heteroreceptors affecting the release of acetylcholine and of amino acid neurotransmitters in the basal ganglia are also relevant for Parkinson's disease. Peripheral dopamine heteroreceptors on postganglionic sympathetic terminals influence heart rate and vascular resistance through modulation of noradrenaline release. Blockade of histamine autoreceptors increases histamine synthesis and release and may support higher CNS functions such as arousal, cognition and learning. Peripheral histamine heteroreceptors on C fiber and on postganglionic sympathetic fiber terminals diminish neuropeptide and noradrenaline release, respectively. Both inhibititory effects are beneficial in myocardial ischemia. The inhibition of neuropeptide release also explains the antimigraine effects of some agonists of presynaptic histamine receptors. Upregulation of presynaptic serotonin autoreceptors is probably involved in the pathogenesis of major depression. Correspondingly, antidepressant treatments can be linked with a reduced density of 5-HT autoreceptors. 5-HT Heteroreceptor activation diminishes acetylcholine and GABA release and may therefore increase anxiety. In the periphery, presynaptic 5-HT heteroreceptor agonists shorten migraine attacks by inhibition of the release of neuropeptides from trigeminal afferents, apart from their constrictive action on meningeal vessels.
Collapse
MESH Headings
- Animals
- Dopamine/metabolism
- Dopamine Agents/pharmacology
- Dopamine Agents/therapeutic use
- Histamine Antagonists/pharmacology
- Histamine Antagonists/therapeutic use
- Humans
- Nervous System Diseases/drug therapy
- Receptors, Dopamine/drug effects
- Receptors, Dopamine/metabolism
- Receptors, Dopamine/physiology
- Receptors, Histamine/drug effects
- Receptors, Histamine/metabolism
- Receptors, Histamine/physiology
- Receptors, Presynaptic/drug effects
- Receptors, Presynaptic/metabolism
- Receptors, Presynaptic/physiology
- Receptors, Serotonin/drug effects
- Receptors, Serotonin/metabolism
- Receptors, Serotonin/physiology
- Serotonin Agents/pharmacology
- Serotonin Agents/therapeutic use
Collapse
Affiliation(s)
- Thomas J Feuerstein
- Neurochirurgische Universitätsklinik Breisacherstrasse, 64 D - 79106, Freiburg, Germany.
| |
Collapse
|
6
|
|
7
|
Goodman A. Neurobiology of addiction. An integrative review. Biochem Pharmacol 2007; 75:266-322. [PMID: 17764663 DOI: 10.1016/j.bcp.2007.07.030] [Citation(s) in RCA: 224] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2007] [Revised: 07/22/2007] [Accepted: 07/23/2007] [Indexed: 02/08/2023]
Abstract
Evidence that psychoactive substance use disorders, bulimia nervosa, pathological gambling, and sexual addiction share an underlying biopsychological process is summarized. Definitions are offered for addiction and addictive process, the latter being the proposed designation for the underlying biopsychological process that addictive disorders are hypothesized to share. The addictive process is introduced as an interaction of impairments in three functional systems: motivation-reward, affect regulation, and behavioral inhibition. An integrative review of the literature that addresses the neurobiology of addiction is then presented, organized according to the three functional systems that constitute the addictive process. The review is directed toward identifying candidate neurochemical substrates for the impairments in motivation-reward, affect regulation, and behavioral inhibition that could contribute to an addictive process.
Collapse
Affiliation(s)
- Aviel Goodman
- Minnesota Institute of Psychiatry, 1347 Summit Avenue, St. Paul, MN 55105, USA.
| |
Collapse
|
8
|
Sarter M, Bruno JP, Parikh V. Abnormal neurotransmitter release underlying behavioral and cognitive disorders: toward concepts of dynamic and function-specific dysregulation. Neuropsychopharmacology 2007; 32:1452-61. [PMID: 17164812 DOI: 10.1038/sj.npp.1301285] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Abnormalities in the regulation of neurotransmitter release and/or abnormal levels of extracellular neurotransmitter concentrations have remained core components of hypotheses on the neuronal foundations of behavioral and cognitive disorders and the symptoms of neuropsychiatric and neurodegenerative disorders. Furthermore, therapeutic drugs for the treatment of these disorders have been developed and categorized largely on the basis of their effects on neurotransmitter release and resulting receptor stimulation. This perspective stresses the theoretical and practical implications of hypotheses that address the dynamic nature of neurotransmitter dysregulation, including the multiple feedback mechanisms regulating synaptic processes, phasic and tonic components of neurotransmission, compartmentalized release, differentiation between dysregulation of basal vs activated release, and abnormal release from neuronal systems recruited by behavioral and cognitive activity. Several examples illustrate that the nature of the neurotransmitter dysregulation in animal models, including the direction of drug effects on neurotransmitter release, depends fundamentally on the state of activity of the neurotransmitter system of interest and on the behavioral and cognitive functions recruiting these systems. Evidence from evolving techniques for the measurement of neurotransmitter release at high spatial and temporal resolution is likely to advance hypotheses describing the pivotal role of neurotransmitter dysfunction in the development of essential symptoms of major neuropsychiatric disorders, and also to refine neuropharmacological mechanisms to serve as targets for new treatment approaches. The significance and usefulness of hypotheses concerning the abnormal regulation of the release of extracellular concentrations of primary messengers depend on the effective integration of emerging concepts describing the dynamic, compartmentalized, and activity-dependent characteristics of dysregulated neurotransmitter systems.
Collapse
Affiliation(s)
- Martin Sarter
- Department of Psychology, University of Michigan, Ann Arbor, MI 48109-1043, USA.
| | | | | |
Collapse
|
9
|
Niewiadomska G, Baksalerska-Pazera M, Gasiorowska A, Mietelska A. Nerve Growth Factor Differentially Affects Spatial and Recognition Memory in Aged Rats. Neurochem Res 2006; 31:1481-90. [PMID: 17111224 DOI: 10.1007/s11064-006-9209-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2006] [Accepted: 10/20/2006] [Indexed: 10/23/2022]
Abstract
In rats, object discrimination depends on the integrity of the cholinergic system, thus it could be expected that nerve growth factor (NGF) can improve the behavior in aged subjects. The interactive effect of age and cholinergic improvement was assessed behaviorally in young and aged rats. Animals were injected by infusion of NGF into the lateral ventricles and they were tested in two behavioral tasks: an object-location and an object-recognition task. Spatial and recognition memory were assessed in an open field containing five different objects. Rats were submitted to six consecutive sessions. Both age-groups showed comparable habituation of exploratory response in Session 1-4. Discrimination index (DI) was calculated to assess responses to spatial change in Session 5 and object change in Session 6. Control young and aged rats were able to discriminate between familiar and novel object, however DI was lower in aged rats. Treatment with NGF induced decline of object discrimination in both age-groups. Different results were obtained in spatial displacement test. NGF was able to improve spatial memory in aged rats, but had no effect in young controls. These data confer on NGF potential role in improving spatial but not episodic memory in aged rats.
Collapse
Affiliation(s)
- G Niewiadomska
- Department of Neurophysiology, Nencki Institute for Experimental Biology, 02-093, Warsaw, Poland.
| | | | | | | |
Collapse
|
10
|
Redmer A, Kathmann M, Schlicker E. Cannabinoid CB(1) receptor-mediated inhibition of hippocampal acetylcholine release is preserved in aged mice. Br J Pharmacol 2003; 138:1425-30. [PMID: 12721097 PMCID: PMC1573802 DOI: 10.1038/sj.bjp.0705194] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
1. The cannabinoid CB(1) receptor inverse agonist/antagonist SR 141716 increases acetylcholine release in rodent hippocampus and improves memory in some experimental paradigms. Since drugs like SR 141716 may represent a novel class of cognition-enhancing drugs, we wanted to check whether the function of the CB(1) receptor is preserved during ageing. 2. Hippocampal and striatal slices from 2- to 3- and 24- to 28-month-old C57BL/6J mice were preincubated with [(3)H]-choline or [(3)H]-noradrenaline ([(3)H]-NA) and superfused. 3. The cannabinoid receptor agonist WIN 55212-2 inhibited, and SR 141716 facilitated, the electrically (3 Hz) evoked tritium overflow in hippocampal slices (preincubated with [(3)H]-choline) from young and aged mice to the same extent. The evoked overflow per se was less by 33% in slices from aged animals. 4. WIN 55212-2 and SR 141716 did not affect, but the muscarinic receptor agonist oxotremorine inhibited, the evoked (3 Hz) overflow in striatal slices (preincubated with [(3)H]-choline) from young and aged mice to the same extent. The evoked overflow per se tended to be less in slices from aged animals. 5. The evoked (0.3 Hz) overflow in hippocampal slices (preincubated with [(3)H]-NA) was not affected by WIN 55212-2 and SR 141716, but was inhibited by histamine (via H(3) receptors) in slices from young mice and, to a somewhat less extent, in slices from aged mice. The evoked overflow per se did not differ between age groups. 6. In conclusion, the function of the CB(1) receptor involved in the tonic inhibition of hippocampal acetylcholine release is preserved in aged mice.
Collapse
Affiliation(s)
- Agnes Redmer
- Institut für Pharmakologie und Toxikologie, Universität Bonn, Reuterstr. 2b, 53113 Bonn, Germany
| | - Markus Kathmann
- Institut für Pharmakologie und Toxikologie, Universität Bonn, Reuterstr. 2b, 53113 Bonn, Germany
| | - Eberhard Schlicker
- Institut für Pharmakologie und Toxikologie, Universität Bonn, Reuterstr. 2b, 53113 Bonn, Germany
- Author for correspondence:
| |
Collapse
|
11
|
Herpfer I, Lieb K. Substance P and Substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry 2003; 4:56-63. [PMID: 12692775 DOI: 10.3109/15622970309167952] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Substance P (SP) is a neuropeptide which is widely distributed in the periphery and the central nervous system (CNS), where it is co-localised with other neurotransmitters such as serotonin or dopamine and where it acts as a neuromodulator. SP has been proposed to play a role in the aetiopathology of asthma, inflammatory bowel disease, emesis, psoriasis, as well as neuropsychiatric disorders including pain syndromes (e.g. migraine and fibromyalgia) and affective disorders, anxiety disorders, schizophrenia and Alzheimer's disease. This review focuses on the role of SP in the pathogenesis of affective disorders. It summarises the current knowledge on measurements of SP in the CSF and serum in patients with depressive disorders or fibromyalgia, effects of SP-application in humans, SP-receptor expression in postmortem brains and the modulation of SP levels in the course of antidepressant treatment. It also discusses the promise of substance P-receptor antagonists (SPA) for the treatment of affective disorders and their proposed mechanism of action. In summary, much more research is needed to elucidate the role of SP in the pathogenesis of depression. SPA are promising as future drugs for the treatment of affective disorders, but current clinical trials have yet to be completed to draw a firm conclusion. Key words: substance P, neurokinin1-receptor, affective disorders, depression, review.
Collapse
Affiliation(s)
- Inga Herpfer
- Department of Psychiatry and Psychotherapy, University of Freiburg, Germany
| | | |
Collapse
|
12
|
Krenz I, Kalkan D, Wevers A, de Vos RA, Steur EN, Lindstrom J, Pilz K, Nowacki S, Schütz U, Moser N, Witter B, Schröder H. Parvalbumin-containing interneurons of the human cerebral cortex express nicotinic acetylcholine receptor proteins. J Chem Neuroanat 2001; 21:239-46. [PMID: 11382535 DOI: 10.1016/s0891-0618(01)00112-0] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Cholinergic fibers from the basal forebrain are known to contact cholinoceptive cortical pyramidal neurons. Recent electrophysiological studies have revealed that nicotinic acetylcholine receptors are also present in human cerebrocortical interneurons. A direct visualization of nicotinic receptor subunits in cortical interneurons has, however, not yet been performed. We have applied double-immunofluorescence using antibodies against parvalbumin --a marker for the Chandelier and basket cell subpopulation of interneurons--and to the alpha4 and alpha7 subunit proteins of the nicotinic acetylcholine receptor. The vast majority of the parvalbuminergic interneurons was immunoreactive for the alpha4 and the alpha7 nicotinic acetylcholine receptor. Provided these receptors would be functional--as suggested by recent electrophysiological findings--the connectivity pattern of cholinergic afferents appears much more complex than thought before. Not only direct cholinergic impact on cortical projection neurons but also the indirect modulation of these by cholinergic corticopetal fibers contacting intrinsic cortical cells would be possible.
Collapse
Affiliation(s)
- I Krenz
- Department of Anatomy/Neuroanatomy, University of Köln, J. Stelzmann-Strasse 9, D-50931 Koln, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Dean B. A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia. Clin Exp Pharmacol Physiol 2001; 28:74-8. [PMID: 11153542 DOI: 10.1046/j.1440-1681.2001.03401.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
1. The pathological process that precipitates schizophrenia has yet to be identified. However, many lines of evidence suggest that a change in the functioning of the frontal cortex is an important abnormality that underlies schizophrenia. 2. Studies in Brodmann's area 9, obtained post-mortem, have shown changes in 5-hydroxytryptamine 5-HT2A, muscarinic M1 and GABA(A) receptors in tissue from subjects with schizophrenia. 3. Animal studies suggest a site in the cortex where there would be an interaction between serotonergic and cholinergic innervation and that this interaction would involve the 5-HT2A and the M1 receptor. This site, in turn, would be a potent modulator of GABA activity and, hence, levels of GABA(A) receptors. 4. From combining these data, a theoretical site is proposed that, if proven to exist in human cortex, is likely to be central to the pathology of that illness.
Collapse
Affiliation(s)
- B Dean
- The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Australia.
| |
Collapse
|
14
|
Kappes T, Schnierle P, Hauser PC. Evaluation of the potentiometric detection of acetylcholine and other neurotransmitters in capillary electrophoresis. Electrophoresis 2000. [DOI: 10.1002/(sici)1522-2683(20000401)21:7%3c1390::aid-elps1390%3e3.0.co;2-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/11/2023]
|
15
|
Kappes T, Schnierle P, Hauser PC. Evaluation of the potentiometric detection of acetylcholine and other neurotransmitters in capillary electrophoresis. Electrophoresis 2000; 21:1390-4. [PMID: 10826685 DOI: 10.1002/(sici)1522-2683(20000401)21:7<1390::aid-elps1390>3.0.co;2-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
It is demonstrated that acetylcholine may be determined potentiometrically in capillary electrophoresis down to 6 x 10(-7) M with a miniature coated-wire ion selective electrode. The more established amperometric method is not possible for this compound. Similarly, 4-aminobutyric acid (GABA) is not accessible amperometrically; although potentiometric detection was possible, the sensitivity is not good. Other neurotransmitters may be determined by either method, but in these cases amperometric determination is generally favorable. For serotonin the potentiometric detection limit was 4 x 10(-5) M, while for the amperometric method a detection limit of 10(-7) M was found.
Collapse
Affiliation(s)
- T Kappes
- The University of Basel, Department of Chemistry, Switzerland
| | | | | |
Collapse
|
16
|
Suhr R, Balse E, Haaf A, Kelche C, Cassel JC, Jackisch R. Modulation of acetylcholine and 5-hydroxytryptamine release in hippocampal slices of rats with fimbria-fornix lesions and intrahippocampal grafts containing cholinergic and/or serotonergic neurons. Brain Res Bull 1999; 50:15-25. [PMID: 10507467 DOI: 10.1016/s0361-9230(99)00083-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Three-month-old Long-Evans female rats sustained aspirative lesions of the dorsal septohippocampal pathways and, 2 weeks later, received intrahippocampal suspension grafts containing fetal cells from the mesencephalic raphe (rich in serotonergic neurons; RAPHE), the medial septum and the diagonal band of Broca (rich in cholinergic neurons; SEPT), or a mixture of both (COTR). Lesion-only (LES) and sham-operated rats (SHAM) were used as controls. Hippocampal slices of these rats (5-9 month after surgery) were preincubated with [3H]choline or [3H]5-HT, superfused continuously (in the presence of hemicholinium-3 or fluvoxamine) and stimulated electrically (360 pulses, 2 ms, 3 Hz, 26-28 mA) in order to study the presynaptic modulation of acetylcholine (ACh) and serotonin (5-HT) release. The accumulation of [3H]choline and the evoked overflow of [3H]ACh were significantly reduced in slices from LES and RAPHE rats, but reached a close-to-normal level in SEPT and COTR rats. As to accumulation and overflow of [3H]5-HT, the lesion-induced reduction was compensated for only in RAPHE and COTR rats. The relative amount of evoked [3H]5-HT release (in % of tissue-3H) was significantly increased in LES and SEPT rats. Only slight differences (group LES) were found in the sensitivity of muscarinic and serotonergic autoreceptors towards oxotremorine and CP 93,129, respectively. Moreover, CP 93,129 induced a significantly weaker inhibition of ACh release in slices of COTR rats than in all other groups. Using the 5-HT1A receptor agonist 8-OH-DPAT and antagonist Way 100,635, no evidence for a modulatory influence of 5-HT1A receptors was found in RAPHE and COTR rats. It is concluded that despite substantial lesion- and graft-induced changes in the amount of ACh and 5-HT released by hippocampal slices of lesion-only or grafted rats, the presynaptic modulation of these transmitters is only slightly affected by changes in the neuronal environment.
Collapse
Affiliation(s)
- R Suhr
- Institut für Pharmakologie und Toxikologie der Universität Freiburg, Neuropharmakologisches Labor, Germany
| | | | | | | | | | | |
Collapse
|
17
|
Kopf SR, Boccia MM, Baratti CM. AF-DX 116, a presynaptic muscarinic receptor antagonist, potentiates the effects of glucose and reverses the effects of insulin on memory. Neurobiol Learn Mem 1998; 70:305-13. [PMID: 9774523 DOI: 10.1006/nlme.1998.3855] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Male Swiss mice were tested 24 h after training in a one-trial step-through inhibitory avoidance task. Low subeffective doses of d-(+)-glucose (10 mg/kg, ip), but not its stereoisomer l-(-)-glucose (30 mg/kg,ip), administered immediately after training, and AF-DX 116 (0.3 mg/kg,ip), a presynaptic muscarinic receptor antagonist, given 10 min after training, interact to improve retention. Insulin (8 IU/kg, ip) impaired retention when injected immediately after training, and the effects were reversed, in a dose-related manner, by AF-DX 116 (0.3, 1.0, or 3.0 mg/kg, ip) administered 10 min following insulin. Since AF-DX 116 possibly blocks autoreceptors mediating the inhibition of acetylcholine release from cholinergic nerve terminals, the present data support the view that changes in the central nervous system glucose availability, subsequent to modification of circulating glucose levels, influence the activity of central cholinergic mechanisms involved in memory storage of an inhibitory avoidance response in mice.
Collapse
Affiliation(s)
- S R Kopf
- Laboratorio de Neurofarmacología de Procesos de Memoria, Cátedra de Farmacología-Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956-5 degrees Piso, Buenos Aires, 1113, Argentina
| | | | | |
Collapse
|
18
|
Feuerstein TJ, Albrecht C, Wessler I, Zentner J, Jackisch R. delta 1-Opioid receptor-mediated control of acetylcholine (ACh) release in human neocortex slices. Int J Dev Neurosci 1998; 16:795-802. [PMID: 10198826 DOI: 10.1016/s0736-5748(98)00086-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
In slices of human neocortex, prelabelled with [3H]-choline, the release of [3H]-acetylcholine reflects the evoked release of endogenous acetylcholine which was elicited by the same electrical stimulation paradigm. [3H]-Acetylcholine release was depressed by the delta-opioid receptor agonist D-Pen2-D-Pen5-enkephalin. When the nerve endings were depolarized by elevating extracellular potassium the evoked [3H]-acetylcholine release was similarly depressed by D-Pen2-D-Pen5-enkephalin in the absence, but not in the presence, of tetrodotoxin which blocks action potential propagation. Therefore, the delta-opioid receptor inhibiting [3H]-acetylcholine release should not be located to cholinergic nerve terminals, but rather to interneurons. The somatostatin2 receptor partial agonist octreotide per se did not influence action potential-evoked [3H]-acetylcholine release, but prevented the inhibition of release of [3H]-acetylcholine by D-Pen2-D-Pen5-enkephalin. Similarly, the delta 1-opioid receptor antagonist 7-benzylidenenaltrexon per se did not influence [3H]-acetylcholine release, but prevented of the inhibition of release by D-Pen2-D-Pen5-enkephalin. From the present findings we conclude: (1) The evoked release of [3H]-acetylcholine from human neocortex slices reflects the release of endogenous acetylcholine. (2) It is inhibited in an indirect manner by opioid receptors of the delta 1-subtype, which (3) are not localized on cholinergic axon terminals but on soma and dendrites of somatostatin-containing interneurons, where they inhibit somatostatin release. (4) These interneurons innervate cholinergic nerve endings in the human neocortex and appear to facilitate acetylcholine release via somatostatin2 receptors.
Collapse
Affiliation(s)
- T J Feuerstein
- Sektion Klinische Neuropharmakologie, Neurologischen Universitätsklinik, Neurozentrum, Freiburg, Germany.
| | | | | | | | | |
Collapse
|
19
|
Feuerstein TJ, Rossner R, Schumacher M. How to express an effect mean as percentage of a control mean? J Pharmacol Toxicol Methods 1997; 37:187-90. [PMID: 9279773 DOI: 10.1016/s1056-8719(97)00017-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The expression of effects as % of corresponding controls requires to consider the variance of these controls. Fieller's Theorem allows the appropriate calculation of the deviation of % values. The Zero-Method, which wrongly assumes that the variance of controls is zero, may lead to doubtful interpretations, as shown with experimental examples on the inhibition of depolarization-evoked transmitter release.
Collapse
Affiliation(s)
- T J Feuerstein
- Sektion Klinische Neuropharmakologie der Neurologischen Universitätsklinik, Neurozentrum, Freiburg, Germany
| | | | | |
Collapse
|